Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.
Identifieur interne : 001848 ( PubMed/Corpus ); précédent : 001847; suivant : 001849Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.
Auteurs : Gajalakshmi Dakshinamoorthy ; Ramaswamy KalyanasundaramSource :
- Vaccine [ 1873-2518 ] ; 2013.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Animals, Antibodies, Helminth (blood), Antibodies, Helminth (immunology), Antibody Specificity (immunology), Antigens, Helminth (immunology), Brugia malayi (genetics), Brugia malayi (immunology), Disease Models, Animal, Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Helminth Proteins (genetics), Helminth Proteins (immunology), Immunization, Immunoglobulin G (blood), Immunoglobulin G (immunology), Male, Mice, Spleen (immunology), Vaccines (administration & dosage), Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines.
- chemical , blood : Antibodies, Helminth, Immunoglobulin G.
- chemical , genetics : Helminth Proteins.
- chemical , immunology : Antibodies, Helminth, Antigens, Helminth, Helminth Proteins, Immunoglobulin G, Vaccines.
- chemical : Adjuvants, Immunologic.
- genetics : Brugia malayi.
- immunology : Antibody Specificity, Brugia malayi, Elephantiasis, Filarial, Spleen.
- prevention & control : Elephantiasis, Filarial.
- Animals, Disease Models, Animal, Immunization, Male, Mice.
Abstract
Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.
DOI: 10.1016/j.vaccine.2013.10.083
PubMed: 24211167
Links to Exploration step
pubmed:24211167Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.</title><author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24211167</idno><idno type="pmid">24211167</idno><idno type="doi">10.1016/j.vaccine.2013.10.083</idno><idno type="wicri:Area/PubMed/Corpus">001848</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001848</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.</title><author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Animals</term><term>Antibodies, Helminth (blood)</term><term>Antibodies, Helminth (immunology)</term><term>Antibody Specificity (immunology)</term><term>Antigens, Helminth (immunology)</term><term>Brugia malayi (genetics)</term><term>Brugia malayi (immunology)</term><term>Disease Models, Animal</term><term>Elephantiasis, Filarial (immunology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Helminth Proteins (genetics)</term><term>Helminth Proteins (immunology)</term><term>Immunization</term><term>Immunoglobulin G (blood)</term><term>Immunoglobulin G (immunology)</term><term>Male</term><term>Mice</term><term>Spleen (immunology)</term><term>Vaccines (administration & dosage)</term><term>Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Helminth Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term><term>Antigens, Helminth</term><term>Helminth Proteins</term><term>Immunoglobulin G</term><term>Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brugia malayi</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Specificity</term><term>Brugia malayi</term><term>Elephantiasis, Filarial</term><term>Spleen</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Immunization</term><term>Male</term><term>Mice</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24211167</PMID><DateCreated><Year>2013</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.</ArticleTitle><Pagination><MedlinePgn>19-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.10.083</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)01490-4</ELocationID><Abstract><AbstractText>Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dakshinamoorthy</LastName><ForeName>Gajalakshmi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalyanasundaram</LastName><ForeName>Ramaswamy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI064745</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI064745</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI064745</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI30022</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015801">Helminth Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2001 Oct;2(10):947-50</RefSource><PMID Version="1">11547333</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2007 Sep 4;25(36):6618-24</RefSource><PMID Version="1">17681647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2010 Jul 12;28(31):5038-48</RefSource><PMID Version="1">20653106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2012 Mar;26(3):1272-9</RefSource><PMID Version="1">22106367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2002;20:197-216</RefSource><PMID Version="1">11861602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dermatol Ther. 2009 Mar-Apr;22(2):97-103</RefSource><PMID Version="1">19335721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2009 Oct 9;27(43):5956-63</RefSource><PMID Version="1">19679214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1989 Jun;40(6):598-604</RefSource><PMID Version="1">2662785</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Micron. 2012 Feb;43(2-3):192-200</RefSource><PMID Version="1">21831642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 Jul 1;183(1):51-8</RefSource><PMID Version="1">19535638</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immune Netw. 2013 Feb;13(1):10-5</RefSource><PMID Version="1">23559895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2011 Feb;79(2):838-45</RefSource><PMID Version="1">21078849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1122-31</RefSource><PMID Version="1">23447566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2003;21:685-711</RefSource><PMID Version="1">12615891</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomed Biotechnol. 2012;2012:831486</RefSource><PMID Version="1">22505817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2011 May;127 Suppl 1:S9-15</RefSource><PMID Version="1">21502246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2013 Mar 15;31(12):1616-22</RefSource><PMID Version="1">23036503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2004 Aug;72(8):4707-15</RefSource><PMID Version="1">15271932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Res Rep Trop Med. 2011 Mar;2011(2):45-56</RefSource><PMID Version="1">21760754</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1993 Aug 12;690:265-75</RefSource><PMID Version="1">8368743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2007 Jun 28;25(27):4985-6</RefSource><PMID Version="1">17543429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(10):e77394</RefSource><PMID Version="1">24146990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2013 Jan 11;31(4):653-60</RefSource><PMID Version="1">23200935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Subcell Biochem. 2010;53:303-21</RefSource><PMID Version="1">20593273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 1998 Jun;66(6):2859-65</RefSource><PMID Version="1">9596760</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(4):e34077</RefSource><PMID Version="1">22496777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Vaccines. 2013 Jul;12(7):705-6</RefSource><PMID Version="1">23885812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2009 Apr;9(4):287-93</RefSource><PMID Version="1">19247370</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Infect Dis. 1980 May-Jun;2(3):370-83</RefSource><PMID Version="1">6997966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 1998 Jul 6;32(3):155-172</RefSource><PMID Version="1">10837642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Parasitol. 2007 Aug;116(4):483-91</RefSource><PMID Version="1">17442307</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Immunol. 2005 Aug;17(4):411-8</RefSource><PMID Version="1">15950445</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2000 May;68(5):3034-5</RefSource><PMID Version="1">10769010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Parasitol. 2011 Nov;129(3):247-53</RefSource><PMID Version="1">21864531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="Y">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015801" MajorTopicYN="N">Helminth Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS537279</OtherID><OtherID Source="NLM">PMC3866973</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADCC</Keyword><Keyword MajorTopicYN="N">Adjuvant</Keyword><Keyword MajorTopicYN="N">Alum</Keyword><Keyword MajorTopicYN="N">Brugia malayi</Keyword><Keyword MajorTopicYN="N">Lymphatic filariasis</Keyword><Keyword MajorTopicYN="N">TLR-4 agonist</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24211167</ArticleId><ArticleId IdType="pii">S0264-410X(13)01490-4</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2013.10.083</ArticleId><ArticleId IdType="pmc">PMC3866973</ArticleId><ArticleId IdType="mid">NIHMS537279</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001848 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001848 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24211167
|texte= Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24211167" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |